Current Role of Ivabradine in Stable Coronary Artery Disease Without Heart Failure

Current Cardiology Reports
Mateo Porres-AguilarAamer Abbas

Abstract

Increase in heart rate represents a significant contribution in the pathophysiology of coronary artery disease and heart failure, by promoting atherosclerotic process and endothelial dysfunction. Thus, it negatively influences cardiovascular risk in the general population. The aim of this review is to analyze the current, controversial, and future role of ivabradine as an anti-anginal agent in the setting of coronary artery disease without heart failure. Ivabradine represents a selective heart rate-lowering agent that increased diastolic perfusion time and improving energetics in the ischemic myocardium.

References

Jun 1, 1987·American Heart Journal·W B KannelL A Cupples
Oct 8, 1997·Journal of the American College of Cardiology·H J Levine
Oct 11, 2005·European Heart Journal·Jean-Claude TardifUNKNOWN INITIATIVE Investigators
Feb 3, 2006·International Journal of Clinical Practice·S Sulfi, A D Timmis
Feb 20, 2010·Circulation Research·Dario DiFrancesco
Oct 30, 2012·Current Treatment Options in Cardiovascular Medicine·Kelly Axsom, Sripal Bangalore
Sep 2, 2014·The New England Journal of Medicine·Kim FoxUNKNOWN SIGNIFY Investigators
Dec 3, 2014·The American Journal of Medicine·Michael BöhmJeffrey S Borer
Apr 30, 2015·European Heart Journal·Roberto Ferrari, Kim M Fox

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Brain Ischemia

Brain ischemia is a condition in which there is insufficient blood flow to the brain to meet metabolic demand. Discover the latest research on brain ischemia here.